Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30006157HIVENSG00000139626.16protein_codingITGB7NoNo3695P26010
TVIS30011730HIVENSG00000139626.16protein_codingITGB7NoNo3695P26010
TVIS30021227HIVENSG00000139626.16protein_codingITGB7NoNo3695P26010
TVIS20020554HPVENSG00000139626.16protein_codingITGB7NoNo3695P26010
TCGA Plot Options
Drug Information
GeneITGB7
DrugBank IDDB12189
Drug NameEtrolizumab
Target IDBE0003414
UniProt IDP26010
Regulation Typebinder
PubMed IDs21232034; 30774593
CitationsStefanich EG, Danilenko DM, Wang H, O'Byrne S, Erickson R, Gelzleichter T, Hiraragi H, Chiu H, Ivelja S, Jeet S, Gadkari S, Hwang O, Fuh F, Looney C, Howell K, Albert V, Balazs M, Refino C, Fong S, Iyer S, Williams M: A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol. 2011 Apr;162(8):1855-70. doi: 10.1111/j.1476-5381.2011.01205.x.@@Lichnog C, Klabunde S, Becker E, Fuh F, Tripal P, Atreya R, Klenske E, Erickson R, Chiu H, Reed C, Chung S, Neufert C, Atreya I, McBride J, Neurath MF, Zundler S: Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. Front Pharmacol. 2019 Feb 1;10:39. doi: 10.3389/fphar.2019.00039. eCollection 2019.
GroupsInvestigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKB
ChEMBL